Get started
Author

Tom Linz

Observed institution: Catalent (United States)
ORCID: 0009-0001-7745-3345
Observed ORCID: 0009-0001-7745-3345
OpenAlex ID: A5119378277
Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al. · Molecular Cancer Therapeutics · 4
PDF
Data from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table 1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S6 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S7 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S8 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S7 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S6 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S8 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Works count: 23
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type